Using statistical models to assess medical cost of hepatitis C virus

Gastroenterology and Hepatology from Bed to Bench

Volumn 5, Issue SUPPL. 1, 2012, Pages

  Vahedi, Mohsen ^a   Pourhoseingholi, Asma ^b   Ashtari, Sara ^b   Pourhoseingholi, Mohamad Amin ^b   Karkhane, Maryam ^b   Moghimi Dehkordi, Bijan ^b   Safaee, Azadeh ^b   Kimia, Zahra ^b   Alavian, Seyed Moayed ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis C; Costs; Negative binomial regression; Poisson regression; Predictive models

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; BINOMIAL DISTRIBUTION; CHI SQUARE TEST; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DRUG COST; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL COST; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL FEE; POISSON DISTRIBUTION; PREDICTION; REGRESSION ANALYSIS; STATISTICAL MODEL;

EID: 84858734892     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436-41.
2. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. Gastroenterol Hepatol Bed Bench 2010; 3:5-14.
3. Alavian SM. New globally faces of hepatitis B and C in the world. Gastroenterol Hepatol Bed Bench 2011; 4:171-74.
4. Alavian SM, Alavian SH, Ashayeri N, Babaei M, Daneshbodi M, Hajibeigi B. Prediction of liver histological lesions with biochemical markers in chronic hepatitis B patients in Iran. Gastroenterol Hepatol Bed Bench 2010; 3:71-76.
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
6. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med 2005; 8:84-90.
7. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol 2003; 38:S104-18.
8. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 2010; 14:e113-16.
9. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999; 20:125-44.
10. Agresti A. An Introduction to Categorical Data Analysis. 2 ed. New York: John Wiley & Sons, Inc; 2007.
11. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol bull 1995; 118:392-404.
12. Hardin J, Hilbe J. Generalized Linear Models and Extensions: Stat-Corp LP, Texas: A Stata Press Publication; 2007.
13. Mullahy J. specification and testing of some modified count data models. J Econometrics 1986; 33:341-65.
14. Lambert D. Zero-inflated Poisson regression, with application to defects in manufacturing. Technometrics 1992; 34:1-14.
15. Vuong Q. Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica 1989; 57:307-33.
16. Picard R, Cook DJ. Cross-Validation of Regression Models. J Am Stat Assoc 1984; 79:575-83.
17. Baughman L. Mixture model framework facilitates understanding of zero-inflated and hurdle models for count data. J Biopharmac Stat 2007; 17:943-46.
18. Gilthorpe MS, Frydenberg M, Cheng Y, Baelum V. Modelling count data with excessive zeros: the need for class prediction in zero-inflated models and the issue of data generation in choosing between zero-inflated and generic mixture models for dental caries data. Stat Med 2009; 28:3539-53.
19. Myers RH, & Montgomery DC. A tutorial on generalized linear models. J Qual Tech 1997; 29:274-
20. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-
21. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
22. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-100.
23. Dwivedi AK, Dwivedi SN, Deo S, Shukla R, Kopras E. Statistical models for predicting number of involved nodes in breast cancer patients. Health 2010; 2:641-51.
24. Blough DK. Using Generalized Linear Models to Assess Medical Care Costs. Health Serv Outcomes Res Methodol 2000; 1:185-202.
25. Duan N, Manning Jr, Morris CN, Newhouse JP. A Comparison of Alternative Models for the Demand for Medical Care. J Business Econ Stat 1993; 1:115-26.
26. Ramsey S, Newton K, Blough D, McCulloch D, Sandhu N, Wagner E. Patient-Level Estimates of the Cost of Complications in Diabetes in a Managed Care Population. Pharmacoeconomics 1999; 196:285-95.
27. Moran JL, Solomon PJ, Peisach AR, Martin J. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract 2007; 13:381-89.
28. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004; 9:197-204.